File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: Diagnostic performance of dual-tracer positron emission tomography-CT with 18F-fluorodeoxyglucose and 11C-acetate versus modified response evaluation criteria in solid tumors in the assessment of residual viable tumours in HCC that received loco-regional therapy

TitleDiagnostic performance of dual-tracer positron emission tomography-CT with 18F-fluorodeoxyglucose and 11C-acetate versus modified response evaluation criteria in solid tumors in the assessment of residual viable tumours in HCC that received loco-regional therapy
Authors
Issue Date2018
PublisherSpringerOpen. The Journal's web site is located at http://www.springer.com/medicine/radiology/journal/13244
Citation
The 29th Annual Meeting and Postgraduate Course of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR 2018), Dublin, Ireland, 12-15 June 2018. In Insights into Imaging, 2018, v. 9 n. 2, Suppl., p. S696, abstract no. SS 15.2 How to Cite?
AbstractPurpose: Dual-tracer positron emission tomography (DT-PET) with 11C-acetate (Ac) and 18F-fluorodeoxyglucose (FDG) have shown to be highly sensitive in the detection of HCC although thus far, it has only been applied to treatment-naïve patients. The aim of this study was to evaluate the diagnostic performance DT-PET in assessing HCC that had undergone loco-regional treatment. Material and methods: Patients with HCC who received loco-regional treatment were retrospectively identified and included if they underwent CT or MRI and DT-PET within 3 months of resection of the lesion. All lesions were evaluated on cross-sectional imaging using the modified response evaluation criteria in solid tumours (mRECIST) and radiotracer uptake on PET were recorded and compared with histology. Results: Fourteen patients with 30 HCC fulfilled the inclusion criteria; 11 underwent transarterial chemoembolization (TACE), 2 radiofrequency ablation (RFA) and 1 both RFA and TACE (median time from previous intervention 3 months, range 1-43 months). Residual tumour was present in 24 lesions on histology. Using mRECIST criteria, 16/30 lesions had complete response, 14 partial response/stable disease. FDG was avid in 15/30, Ac in 20/30 and DT PET in 22/30 lesions. The positive predictive values for both modalities were 100% and the sensitivities in detecting residual disease were 54.2% and 83.3% (p<0.05) for cross-sectional imaging and DT-PET, respectively. Conclusion: mRECIST criteria on cross-sectional imaging under-detect residual viable tumour in HCC that had undergone loco-regional treatment. DTPET is a sensitive modality that can be used as an alternative modality for the treatment reassessment especially in cases where patients’ management may be altered.
Persistent Identifierhttp://hdl.handle.net/10722/260693
ISSN
2019 Impact Factor: 3.579
2015 SCImago Journal Rankings: 1.004

 

DC FieldValueLanguage
dc.contributor.authorChiu, WHK-
dc.contributor.authorCheung, TT-
dc.contributor.authorLo, CLR-
dc.contributor.authorYuan, H-
dc.contributor.authorChan, LW-
dc.date.accessioned2018-09-14T08:45:48Z-
dc.date.available2018-09-14T08:45:48Z-
dc.date.issued2018-
dc.identifier.citationThe 29th Annual Meeting and Postgraduate Course of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR 2018), Dublin, Ireland, 12-15 June 2018. In Insights into Imaging, 2018, v. 9 n. 2, Suppl., p. S696, abstract no. SS 15.2-
dc.identifier.issn1869-4101-
dc.identifier.urihttp://hdl.handle.net/10722/260693-
dc.description.abstractPurpose: Dual-tracer positron emission tomography (DT-PET) with 11C-acetate (Ac) and 18F-fluorodeoxyglucose (FDG) have shown to be highly sensitive in the detection of HCC although thus far, it has only been applied to treatment-naïve patients. The aim of this study was to evaluate the diagnostic performance DT-PET in assessing HCC that had undergone loco-regional treatment. Material and methods: Patients with HCC who received loco-regional treatment were retrospectively identified and included if they underwent CT or MRI and DT-PET within 3 months of resection of the lesion. All lesions were evaluated on cross-sectional imaging using the modified response evaluation criteria in solid tumours (mRECIST) and radiotracer uptake on PET were recorded and compared with histology. Results: Fourteen patients with 30 HCC fulfilled the inclusion criteria; 11 underwent transarterial chemoembolization (TACE), 2 radiofrequency ablation (RFA) and 1 both RFA and TACE (median time from previous intervention 3 months, range 1-43 months). Residual tumour was present in 24 lesions on histology. Using mRECIST criteria, 16/30 lesions had complete response, 14 partial response/stable disease. FDG was avid in 15/30, Ac in 20/30 and DT PET in 22/30 lesions. The positive predictive values for both modalities were 100% and the sensitivities in detecting residual disease were 54.2% and 83.3% (p<0.05) for cross-sectional imaging and DT-PET, respectively. Conclusion: mRECIST criteria on cross-sectional imaging under-detect residual viable tumour in HCC that had undergone loco-regional treatment. DTPET is a sensitive modality that can be used as an alternative modality for the treatment reassessment especially in cases where patients’ management may be altered.-
dc.languageeng-
dc.publisherSpringerOpen. The Journal's web site is located at http://www.springer.com/medicine/radiology/journal/13244-
dc.relation.ispartofInsights into Imaging-
dc.relation.ispartofThe 29th Annual Meeting and Postgraduate Course of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR 2018)-
dc.titleDiagnostic performance of dual-tracer positron emission tomography-CT with 18F-fluorodeoxyglucose and 11C-acetate versus modified response evaluation criteria in solid tumors in the assessment of residual viable tumours in HCC that received loco-regional therapy-
dc.typeConference_Paper-
dc.identifier.emailChiu, WHK: kwhchiu@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailLo, CLR: loregina@hku.hk-
dc.identifier.authorityChiu, WHK=rp02074-
dc.identifier.authorityCheung, TT=rp02129-
dc.identifier.authorityLo, CLR=rp01359-
dc.identifier.doi10.1007/s13244-018-0634-1-
dc.identifier.hkuros290723-
dc.identifier.volume9-
dc.identifier.issue2, Suppl.-
dc.identifier.spageS696, abstract no. SS 15.2-
dc.identifier.epageS696, abstract no. SS 15.2-
dc.publisher.placeGermany-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats